Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It

RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and partly because the science moved. When dermatologists, facial plastic surgeons and aesthetic medicine specialists gather this week at the Controversies & Conversations in Laser & Cosmetic Surgery Symposium, one of the presentations will argue the field needs a different blueprint entirely. That case will be made by the Chief Medical Officer of Conexeu Sciences Inc. (Nasdaq: CNXU), a preclinical-stage company whose lead device candidate is designed to turn from liquid into an extracellular matrix inside the body in about ten minutes. Investors tracking how regenerative approaches are moving from theory into commercial medicine may also want to watch Vericel Corporation (Nasdaq: VCEL), Axogen, Inc. (Nasdaq: AXGN), Krystal Biotech, Inc. (Nasdaq: KRYS), and Envista Holdings Corporation (NYSE: NVST).